Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial
| Autor: | Aedin Cassidy, Manuel Y. Schär, Sara Hazim, Luisa M. Ostertag, Anne Marie Minihane, Colin D. Kay, Peter J. Curtis |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Medicine (miscellaneous) 030204 cardiovascular system & hematology Placebo Equol producer phenotype 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine SDG 3 - Good Health and Well-being Internal medicine medicine CVD risk Flavonoids 030109 nutrition & dietetics Nutrition and Dietetics business.industry Daidzein food and beverages Equol Vascular function Isoflavones medicine.disease Arterial stiffness Isoflavone Crossover study Blood pressure Endocrinology chemistry Phytoestrogens business |
| Zdroj: | Hazim, S, Curtis, P J, Schär, M Y, Ostertag, L M, Kay, C D, Minihane, A M & Cassidy, A 2016, ' Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype : A double-blind randomized controlled trial ', American Journal of Clinical Nutrition, vol. 103, no. 3, pp. 694-702 . https://doi.org/10.3945/ajcn.115.125690 |
| ISSN: | 0002-9165 |
| DOI: | 10.3945/ajcn.115.125690 |
| Popis: | Background: There is much speculation with regard to the potential cardioprotective benefits of equol, a microbial-derived metabolite of the isoflavone daidzein, which is produced in the large intestine after soy intake in 30% of Western populations. Although cross-sectional and retrospective data support favorable associations between the equol producer (EP) phenotype and cardiometabolic health, few studies have prospectively recruited EPs to confirm this association. Objective: The aim was to determine whether the acute vascular benefits of isoflavones differ according to EP phenotype and subsequently investigate the effect of providing commercially produced S-(–)equol to non-EPs. Design: We prospectively recruited male EPs and non-EPs (n = 14/group) at moderate cardiovascular risk into a double-blind, placebo-controlled crossover study to examine the acute effects of soy isoflavones (80-mg aglycone equivalents) on arterial stiffness [carotid-femoral pulse-wave velocity (cfPWV)], blood pressure, endothelial function (measured by using the EndoPAT 2000; Itamar Medical), and nitric oxide at baseline (0 h) and 6 and 24 h after intake. In a separate assessment, non-EPs consumed 40 mg S-(–)equol with identical vascular measurements performed 2 h after intake. Results: After soy intake, cfPWV significantly improved in EPs at 24 h (cfPWV change from 0 h: isoflavone, −0.2 ± 0.2 m/s; placebo, 0.6 ± 0.2 m/s; P < 0.01), which was significantly associated with plasma equol concentrations (R = −0.36, P = 0.01). No vascular effects were observed in EPs at 6 h or in non-EPs at any time point. Similarly, no benefit of commercially produced S-(–)equol was observed in non-EPs despite mean plasma equol concentrations reaching 3.2 μmol/L. Conclusions: Acute soy intake improved cfPWV in EPs, equating to an 11–12% reduced risk of cardiovascular disease if sustained. However, a single dose of commercially produced equol had no cardiovascular benefits in non-EPs. These data suggest that the EP phenotype is critical in unlocking the vascular benefits of equol in men, and long-term trials should focus on confirming the implications of EP phenotype on cardiovascular health. This trial was registered at clinicaltrials.gov as {"type":"clinical-trial","attrs":{"text":"NCT01530893","term_id":"NCT01530893"}}NCT01530893. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|